Company
Ascensia Diabetes Care
Last checked: Nov 21, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
13
510(k), De Novo and PMA
Device trials
41
As lead sponsor, any status
Adverse event reports
74
Received Nov 1, 2025 to Nov 21, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Ascensia Diabetes Care, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors from funding announcements and the firms' own portfolio pages.
No 5%+ shareholder filings, SBIR grants or venture investors found under the name Ascensia Diabetes Care.
Latest FDA decisions
The 8 newest of 13 since 2015.
K260545 · Decided Aug 27, 2026 · 190 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
12 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT05467345 · 120 participants · Start Aug 24, 2022 · Primary completion Nov 30, 2022
Device: Contour Next and Contour Plus Elite BGMS testing of neonatal blood · For: Diabetes Mellitus
Sites: St Louis, Missouri
40 more trials with a free account
Reports received
74
Received Nov 1, 2025 to Nov 21, 2026
Malfunction reports
66
89% of reports
Injury reports
8
11% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 21 | 1 | 0 | 0 |
| Jan 24 | 13 | 0 | 0 | 0 |
| Feb 24 | 12 | 1 | 0 | 0 |
| Mar 24 | 21 | 4 | 0 | 0 |
| Apr 24 | 17 | 1 | 0 | 0 |
| May 24 | 13 | 2 | 0 | 0 |
| Jun 24 | 19 | 2 | 0 | 0 |
| Jul 24 | 17 | 0 | 0 | 0 |
| Aug 24 | 19 | 0 | 0 | 0 |
| Sep 24 | 12 | 0 | 0 | 0 |
| Oct 24 | 13 | 0 | 0 | 0 |
| Nov 24 | 12 | 1 | 0 | 0 |
| Dec 24 | 14 | 1 | 0 | 0 |
| Jan 25 | 15 | 3 | 0 | 0 |
| Feb 25 | 10 | 0 | 0 | 0 |
| Mar 25 | 22 | 2 | 0 | 0 |
| Apr 25 | 11 | 2 | 0 | 0 |
| May 25 | 15 | 1 | 0 | 0 |
| Jun 25 | 18 | 0 | 0 | 0 |
| Jul 25 | 13 | 1 | 0 | 0 |
| Aug 25 | 13 | 0 | 0 | 0 |
| Sep 25 | 17 | 0 | 0 | 0 |
| Oct 25 | 10 | 2 | 0 | 0 |
| Nov 25 | 4 | 0 | 0 | 0 |
| Dec 25 | 7 | 0 | 0 | 0 |
| Jan 26 | 3 | 1 | 0 | 0 |
| Feb 26 | 7 | 1 | 0 | 0 |
| Mar 26 | 1 | 0 | 0 | 0 |
| Apr 26 | 10 | 0 | 0 | 0 |
| May 26 | 3 | 0 | 0 | 0 |
| Jun 26 | 8 | 0 | 0 | 0 |
| Jul 26 | 3 | 0 | 0 | 0 |
| Aug 26 | 6 | 2 | 0 | 0 |
| Sep 26 | 11 | 4 | 0 | 0 |
| Oct 26 | 3 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
The full in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Contour next GEN Blood Glucose Monitoring SystemOpen, Classified
Z-2211-2023 · Started May 19, 2023 · Posted by FDA Jul 20, 2023
Reason given: Ascensia Diabetes Care has determined through customer complaints that 580 of 2900 meters from lot number DM01T033P are reconfigured from mg/dL to mmol/L. Among them, 579 meters distributed in the United States were packaged into the meter kit and had incorrect factory-set unit of measure where the meters display...
Cause as FDA categorized it: Process control · Device type: System, Test, Blood Glucose, Over The Counter (NBW)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.